欢迎访问《现代生物医学进展》编辑部！

目的：探讨不同新辅助化疗方案对多药耐药相关蛋白在骨肉瘤组织中表达的影响。方法：采用RP-PCR 技术以及免疫组化技术检测48 例骨肉瘤患者在不同新辅助化疗方案实施前后多药耐药相关蛋白在mRNA 以及蛋白水平的表达变化。结果：在同一新辅助化疗方案实施前后以及不同新辅助化疗方案之间，肿瘤组织的多药耐药蛋白的mRNA 及蛋白表达均无显著性差异。结论：不同新辅助化疗方案的实施对骨肉瘤多药耐药蛋白表达的影响有限，其多药耐药性可能主要决定于肿瘤本身，检测多药耐药蛋白的表达有利于制定个体化化疗方案。

英文摘要:

Objective: To explore the effect of different neoadjuvant chemotherapy on the expression of multidrug resistance-associated protein in osteosarcoma. Methods: RP-PCR and immunohistochemical techniques were used to detect the expression of multi-drug resistance-associated protein mRNA and protein in 48 cases of osteosarcoma patients before and after the implementation of neoadjuvant chemotherapy. Results: There was no significant difference in MDR expression between before and after neoadjuvant chemotherapy, and there was no difference between two types of neoadjuvant chemotherapy regimens. Conclusion: The effect of implementation of different neoadjuvant chemotherapies is very limited on expression of multidrug resistance protein in osteosarcoma. The multi-drug resistance of this tumour may be mainly determined by itself. Detection of the multidrug resistance protein expression will facilitate the development of individual chemotherapy.

View Full Text View/Add Comment Download reader